KRON Profile
Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative cancer therapeutics. The company's research and development efforts are centered on targeting dysregulated transcription factors and the complex transcriptional regulatory networks that contribute to oncogenic activity. This focus positions Kronos Bio at the forefront of advancing novel treatments designed to address critical needs in cancer therapy.
The company’s lead product candidate, entospletinib, is an orally administered selective spleen tyrosine kinase (SYK) inhibitor. Entospletinib is being developed for the treatment of acute myeloid leukemia (AML) and is currently undergoing a registrational Phase 3 clinical trial. This trial is evaluating entospletinib in combination with induction chemotherapy for AML patients harboring NPM1 mutations. This innovative approach aims to enhance treatment efficacy and improve patient outcomes in this challenging cancer type.
In addition to entospletinib, Kronos Bio is advancing several other promising drug candidates. KB-0742 is an orally bioavailable inhibitor of cyclin-dependent kinase 9 (CDK9) currently in Phase 1/2 clinical trials. This compound is being developed for the treatment of MYC-amplified solid tumors, a subset of cancers characterized by specific genetic alterations. Lanraplenib, another key development, is a next-generation SYK inhibitor being explored for the treatment of autoimmune diseases, reflecting the company’s broader commitment to addressing diverse therapeutic areas.
Founded in 2017 and headquartered in San Mateo, California, Kronos Bio has quickly established itself as a significant player in the biopharmaceutical industry. The company’s strategic focus on novel cancer therapies and its robust pipeline of drug candidates underscore its dedication to advancing innovative treatments and improving patient outcomes in oncology and beyond.
|
